Euformatics partners with Cerba to provide software tools for clinical genomic data analysis
Press Release Espoo, Finland, September 6th, 2023
Euformatics, a world leader in NGS quality control and variant interpretation tools, announced that it has signed a new commercial relationship with Cerba, world reference laboratory in specialized clinical pathology. As part of the collaboration, Euformatics delivers the full Genomics Hub software suite to Cerba to power their NGS test validation, continuous quality control and clinical variant interpretation and reporting workflows.
Partnership also covers consultancy to provide evidence-based quality metrics for different NGS instrument platforms to help Cerba make informed decisions about how to expand their laboratory infrastructure. The basis for this work lies in the External Quality Assessment scheme work that the Euformatics team has done in collaboration with leading EQA providers globally. Cerba needed a software suite that is sequencer-agnostic and had built-in quality control automation in it to ensure their diagnostic work is based on high quality data.
Benedicte Roquebert, Medical Director at Cerba, comments: “We were impressed by the insight that the Euformatics team has on NGS data from a technical and analytical perspective. Their software tools were a great fit for us as we are expanding our lab infrastructure with new sequencers and needed a kit- and sequencer-agnostic solution to enable our geneticists to efficiently diagnose patient samples.”
Euformatics’ CEO, Tommi Kaasalainen adds:“Collaboration with Cerba has been great. They are very professional and demanding which should of course be the case for such a high-profile healthcare organisation. I expect this partnership to be a 2-way street where our product roadmap gets significant input from the customer.”
Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the Genomics Hub which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.
To learn more, visit www.euformatics.com
About laboratoire Cerba
Laboratoire Cerba, at the origin of the Cerba HealthCare Group and world reference in specialized clinical pathology, performs complex analyses on behalf of other medical laboratories that cannot proceed with their own analyses due to the level of expertise, equipment and certification required. For 50 years, Cerba’s medical and scientific teams have been assisting and advising healthcare professionals in the selection of the most relevant analyses and in the interpretation of the results to improve patient care. They are recognized by their peers in human genetics, oncohematology, infectiology, endocrinology and immunology, pharmacotoxicology and metabolic diseases.
With a panel of 1,300 exams covering 40 medical specialties, Cerba serves private and public healthcare institutions in more than 50 countries.
For more information www.lab-cerba.com